PolyPid (PYPD) Competitors $2.85 -0.05 (-1.72%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYPD vs. OBIO, ICAD, GUTS, MBOT, MGRM, FONR, MLSS, SRTS, INO, and ZYXIShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Orchestra BioMed (OBIO), iCAD (ICAD), Fractyl Health (GUTS), Microbot Medical (MBOT), Monogram Orthopaedics (MGRM), FONAR (FONR), Milestone Scientific (MLSS), Sensus Healthcare (SRTS), Inovio Pharmaceuticals (INO), and Zynex (ZYXI). These companies are all part of the "medical equipment" industry. PolyPid vs. Orchestra BioMed iCAD Fractyl Health Microbot Medical Monogram Orthopaedics FONAR Milestone Scientific Sensus Healthcare Inovio Pharmaceuticals Zynex Orchestra BioMed (NASDAQ:OBIO) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk. Do institutionals & insiders believe in OBIO or PYPD? 53.5% of Orchestra BioMed shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 8.1% of Orchestra BioMed shares are held by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in OBIO or PYPD? PolyPid received 11 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 80.00% of users gave PolyPid an outperform vote. CompanyUnderperformOutperformOrchestra BioMedOutperform Votes21100.00% Underperform VotesNo VotesPolyPidOutperform Votes3280.00% Underperform Votes820.00% Do analysts recommend OBIO or PYPD? Orchestra BioMed presently has a consensus price target of $14.20, suggesting a potential upside of 407.14%. PolyPid has a consensus price target of $11.33, suggesting a potential upside of 297.66%. Given Orchestra BioMed's higher probable upside, equities research analysts plainly believe Orchestra BioMed is more favorable than PolyPid.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orchestra BioMed 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20PolyPid 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher earnings and valuation, OBIO or PYPD? PolyPid has lower revenue, but higher earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrchestra BioMed$2.89M37.17-$49.12M-$1.78-1.57PolyPidN/AN/A-$29.02M-$4.30-0.66 Does the media favor OBIO or PYPD? In the previous week, Orchestra BioMed and Orchestra BioMed both had 5 articles in the media. PolyPid's average media sentiment score of 0.60 beat Orchestra BioMed's score of 0.43 indicating that PolyPid is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is OBIO or PYPD more profitable? PolyPid has a net margin of 0.00% compared to Orchestra BioMed's net margin of -2,179.33%. Orchestra BioMed's return on equity of -107.04% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Orchestra BioMed-2,179.33% -107.04% -70.88% PolyPid N/A -624.10%-129.28% Which has more volatility and risk, OBIO or PYPD? Orchestra BioMed has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. SummaryOrchestra BioMed and PolyPid tied by winning 8 of the 16 factors compared between the two stocks. Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.55M$4.55B$5.43B$8.48BDividend YieldN/A43.65%5.22%4.11%P/E Ratio-0.5829.8726.8320.05Price / SalesN/A71.05392.35116.46Price / CashN/A51.0838.2534.62Price / Book3.876.346.874.61Net Income-$29.02M$67.64M$3.22B$248.19M7 Day PerformanceN/A21.94%6.76%2.97%1 Month Performance5.45%26.54%13.66%16.58%1 Year Performance-38.38%22.75%18.27%8.16% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid2.1727 of 5 stars$2.85-1.7%$11.33+297.7%-34.5%$29.04MN/A-0.5780Earnings ReportOBIOOrchestra BioMed2.8577 of 5 stars$2.92+0.7%$14.20+386.3%-43.6%$111.11M$2.89M-1.814ICADiCAD0.4719 of 5 stars$3.98-0.3%N/A+141.5%$109.24M$19.61M-30.62140News CoverageAnalyst ForecastGUTSFractyl Health1.7382 of 5 stars$2.12+25.4%$11.00+418.9%-69.9%$103.83M$93,000.00-0.17102High Trading VolumeMBOTMicrobot Medical1.9468 of 5 stars$2.74+2.2%$9.00+228.5%+162.1%$95.20MN/A-3.4220Positive NewsEarnings ReportGap UpMGRMMonogram Orthopaedics3.1447 of 5 stars$2.69+3.9%$5.40+100.7%+40.1%$94.93M$364,999.00-5.7228Earnings ReportFONRFONAR1.8205 of 5 stars$13.51+4.7%N/A-1.8%$83.91M$101.57M11.75480News CoverageEarnings ReportAnalyst UpgradeHigh Trading VolumeMLSSMilestone Scientific0.5825 of 5 stars$1.02+14.0%$1.25+22.5%+46.9%$79.95M$8.63M-14.5730Analyst ForecastGap DownSRTSSensus Healthcare2.7606 of 5 stars$4.73+6.1%$11.67+146.7%-23.3%$78.02M$41.81M11.8340News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionINOInovio Pharmaceuticals3.7271 of 5 stars$2.07+1.0%$9.75+371.0%-80.8%$75.92M$217,756.00-0.65320ZYXIZynex3.0742 of 5 stars$2.36-4.8%$6.00+154.2%-76.6%$74.99M$172.40M15.73770Gap Down Related Companies and Tools Related Companies Orchestra BioMed Alternatives iCAD Alternatives Fractyl Health Alternatives Microbot Medical Alternatives Monogram Orthopaedics Alternatives FONAR Alternatives Milestone Scientific Alternatives Sensus Healthcare Alternatives Inovio Pharmaceuticals Alternatives Zynex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYPD) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
